---
title: "GLORIA PHARMA: Three senior executives plan to collectively reduce their holdings by 0.0639% of the company's shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242390817.md"
description: "GLORIA PHARMA announced that Vice General Manager Li Runbao, Vice General Manager Wang Xiaohang, and Director, Vice General Manager, and Board Secretary Liu Yueyin plan to reduce their holdings in the company through centralized bidding within three months after 15 trading days from the date of the announcement. Li Runbao and Wang Xiaohang each plan to reduce their holdings by 587,500 shares, accounting for 0.0262% of the company's total share capital; Liu Yueyin plans to reduce his holdings by 259,600 shares, accounting for 0.0116% of the company's total share capital. The reason for the reduction is personal funding needs, and the reduction price will be determined at market price"
datetime: "2025-05-29T11:41:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242390817.md)
  - [en](https://longbridge.com/en/news/242390817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242390817.md)
---

# GLORIA PHARMA: Three senior executives plan to collectively reduce their holdings by 0.0639% of the company's shares

GLORIA PHARMA announced that Vice General Manager Li Runbao, Vice General Manager Wang Xiaohang, and Director, Vice General Manager, and Board Secretary Liu Yueyin plan to reduce their holdings in the company shares through centralized bidding within three months after the announcement is disclosed, starting from 15 trading days later. Li Runbao and Wang Xiaohang each plan to reduce their holdings by 587,500 shares, accounting for 0.0262% of the company's total share capital; Liu Yueyin plans to reduce his holdings by 259,600 shares, accounting for 0.0116% of the company's total share capital. The reason for the reduction is personal funding needs, and the reduction price will be determined at market price

### Related Stocks

- [002437.CN](https://longbridge.com/en/quote/002437.CN.md)

## Related News & Research

- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [ZAWYA: JA Resorts & Hotels announces strategic enhancements across its Dubai portfolio](https://longbridge.com/en/news/287173198.md)
- [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)
- [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)